--- title: "基石藥業宣佈其新型三特異性抗體 CS2009（PD-1/VEGF/CTLA-4）的 IND 申請已獲得 FDA 批准，即將進入 II 期臨牀試驗" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/276018493.md" description: "基石藥業已獲得 FDA 批准，啓動其三特異性抗體 CS2009 的 IND 申請，以開展針對晚期實體瘤的第二階段臨牀試驗。該試驗將評估單藥治療和聯合治療，涵蓋 15 個隊列和 9 個適應症，包括非小細胞肺癌和結直腸癌。初步的第一階段數據表明其安全性良好，並且具有良好的抗腫瘤活性。目前該試驗正在澳大利亞和中國招募患者，預計將在即將舉行的腫瘤學大會上發佈進一步更新" datetime: "2026-02-16T00:22:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276018493.md) - [en](https://longbridge.com/en/news/276018493.md) - [zh-HK](https://longbridge.com/zh-HK/news/276018493.md) --- # 基石藥業宣佈其新型三特異性抗體 CS2009（PD-1/VEGF/CTLA-4）的 IND 申請已獲得 FDA 批准，即將進入 II 期臨牀試驗 - CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received **Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA)** **to initiate a Phase II clinical trial in** **patients with advanced solid tumors.** This marks a significant milestone in the global development of this innovative immunotherapy. - The ongoing global multicenter Phase II trial is currently enrolling patients in Australia and China. The study design includes **15 cohorts** evaluating both monotherapy and combination therapy regimens across **9 solid tumor indications**, including but not limited to: - Non-small cell lung cancer (NSCLC) - Colorectal cancer (CRC) - Triple-negative breast cancer (TNBC) - Extensive-stage small cell lung cancer (ES-SCLC)‌ - Platinum-resistant ovarian cancer (PROC) - Initial Phase I data for CS2009, previously presented at the 2025 European Society for Medical Oncology (ESMO) annual meeting, **demonstrat****ed a favorable safety profile with encouraging antitumor activities.** Further clinical data from both the phase I and II is expected to be disclosed at the upcoming American Society of Clinical Oncology (ASCO) and ESMO congress later this year. SUZHOU, China, Feb. 15, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced that **the U.S. FDA has** **cleared the IND application** **to initiate a Phase II clinical trial of its core asset, CS2009, in** **patients with advanced solid tumors.** **Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone,** stated, "We are pleased to receive FDA clearance to proceed with the global Phase II clinical trial of CS2009. This milestone follows a productive interaction with the agency, during which they reviewed our comprehensive Phase I data—including safety and antitumor activity data collected during dose escalation and expansion—and provided alignment on key elements of the Phase II study design, including dose optimization and expansion strategies. We are now actively advancing CS2009 clinical program globally and look forward to sharing further updates as the study progresses." **About CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)** CS2009, an innovative trispecific antibody designed and developed by CStone, with the potential to be first- or best-in-class. It combines three clinically validated targets—PD-1, VEGFA, and CTLA-4—and exerts multidimensional anti-tumor effects through synergistic actions. Specifically, anti-PD-1 activity reverses T cell exhaustion, anti-CTLA-4 activity promotes T cell activation and proliferation, while anti-VEGFA activity blocks tumor angiogenesis and improves the tumor micro-environment (TME). In the TME, anti-PD-1 and anti-CTLA-4 activities are significantly enhanced by crosslinking with VEGFA. Meanwhile, CS2009 preferentially blocks PD-1 and CTLA-4 on double-positive tumor-infiltrating T cells while minimizing interference with CTLA-4 regulation in peripheral T cells. The ongoing global, multicenter Phase II clinical trial of CS2009 features a multi-cohort, parallel expansion design to evaluate the efficacy, safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of CS2009 as monotherapy and combination regimens. The study comprises 15 monotherapy and combination therapy cohorts across 9 solid tumor indications, including NSCLC, CRC, TNBC, ES-SCLC, PROC, cervical cancer (CC), hepatocellular carcinoma (HCC), gastric or gastroesophageal junction cancer (GC/GEJC), and esophageal squamous cell carcinoma (ESCC). The trial is actively enrolling patients in Australia and China and has received IND clearance in the U.S. **About CStone** CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 20 new drug applications covering 9 indications. The company's pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit: www.cstonepharma.com. **Forward-looking statements** The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments. _Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes._ View original content:https://www.prnewswire.com/news-releases/cstone-announces-fda-clearance-of-ind-application-for-its-novel-trispecific-antibody-cs2009-pd-1vegfctla-4-to-advance-into-phase-ii-clinical-trial-302688307.html SOURCE CStone Pharmaceuticals ### 相關股票 - [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [02616.HK](https://longbridge.com/zh-HK/quote/02616.HK.md) - [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [VRTX.US](https://longbridge.com/zh-HK/quote/VRTX.US.md) - [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [BMRN.US](https://longbridge.com/zh-HK/quote/BMRN.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md) - [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md) ## 相關資訊與研究 - [巨生醫細胞治療產品獲 SelectUSA Tech 醫療領域前 8 強 有助美國市場佈局](https://longbridge.com/zh-HK/news/282988767.md) - [鉅亨速報 - Factset 最新調查：Summit Therapeutics Inc(SMMT-US) EPS 預估上修至-1.2 元，預估目標價為 33.00 元](https://longbridge.com/zh-HK/news/282998825.md) - [基石藥業擬折讓近 7% 配股籌逾 10.5 億加碼腫瘤管線研發](https://longbridge.com/zh-HK/news/282773840.md) - [勞團控突襲取消 RCA 專案健檢 勞動部：持續辦理](https://longbridge.com/zh-HK/news/283102864.md) - [巨生醫細胞治療產品 MPB-2354 獲選 SelectUSA Tech 醫療領域前八強](https://longbridge.com/zh-HK/news/282972944.md)